Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic stem cell transplantation for eradication of minimal residual disease after pancreatic cancer resection
2012-003528-19Phase 2Terminated
- Sponsor
- Heidelberg University
- Start
- Sep 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic hematopoietic stem cells in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Heidelberg University. Primary endpoint: 2-year progression-free survival from registration. Started Sep 2012; status: terminated.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2012-003528-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003528-19.